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tablets in healthy Taiwanese volunteers.
Methods: In this open-label, randomized, 2-period, crossover study, 68 volunteers were randomized to a
single ALN/D5600 combination tablet or corresponding doses of 70 mg ALN þ 5600 IU vitamin D3 (2 
2800 IU), followed by a 12-day washout period and administration of the alternate formulation. Plasma
ALN levels were measured using a newly developed assay. Geometric mean ratios of ALN AUC0–last,
AUC0–1, and Cmax, and unadjusted vitamin D3 AUC0–80h and Cmax were compared and considered
bioequivalent if the 90% CI was within 0.8 to 1.25.
Results: The geometric mean ratios were: AUC0–last, 1.084 (90% CI, 0.937–1.253); AUC0–1, 1.081 (90% CI,
0.935–1.249); and Cmax, 1.112 (90% CI, 0.959–1.289) for ALN, and AUC0–80h 0.953 (90% CI, 0.827–1.098)
and Cmax, 0.982 (90% CI, 0.854–1.130) for vitamin D3 unadjusted for endogenous levels.
Conclusions: The combination tablet was considered bioequivalent to coadministration based on ALN
AUC0–1 and unadjusted vitamin D3 parameters. Slight differences for ALN AUC0–last and Cmax (upper 90%
CIs outside the bounds) were not considered clinically signiﬁcant. The combination tablet was well
tolerated. No serious adverse experiences were reported. © 2015. The Authors. Published by Elsevier Inc.
All rights reserved.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Osteoporosis is estimated to affect 200 million women world-
wide1 and causes an estimated 9.0 million fractures annually.2 In
Taiwan, osteoporosis and associated age-related fractures are a major
public health problem. The Nutrition and Health Survey in Taiwan,
conducted in 2005 to 2008, found prevalence rates of osteoporosis of
23.9% in men and 38.3% in women aged 50 years and older.3 The
prevalence rate of vertebral fractures in urban cities in Taiwan has
been reported as 12.5% in men and 20% in women aged 65 years and
older.4 The incidence of hip fractures was reported to increaseInc. This is an open access article u
hD, Merck Research Labora-
Rd, Kenilworth, NJ 07033.
Wright).between 1996 and 2002, from 496 to 644 per 100,000 persons per
year in Taiwan’s elderly population (aged 65 years and older).5
Providing adequate daily calcium and vitamin D is considered a
safe and inexpensive way to help reduce fracture risk for all
individuals,6 and optimal vitamin D status appears necessary to
maximize the response to antiresorptive therapy.7 The antifracture
effects of vitamin D supplementation also appear to be over and
above those of calcium supplements, which are often given
concurrently.8 Vitamin D deﬁciency (ie, 25-hydroxyvitamin D
[25(OH)D] o20 ng/mL) is common worldwide, with mean pop-
ulation levels of o20 ng/mL reported in 37.3% of 195 studies
published between 1990 and 2011 involving more than 168,000
patients in 44 countries.9 In older adults living in a northern
Taiwan community, the mean 25(OH)D level was 39.9 ng/mL and
31% of the 215 participants had 25(OH)D levels o20 ng/mL.10 In
recent years there has been considerable debate regarding whatnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lines varying in their recommendations for minimal serum 25(OH)
D levels.11 A minimal serum 25(OH)D level of 20 ng/mL12 or 30 ng/
mL6,13 is currently recommended for the general population, and a
level of 30 ng/mL for fragile elderly patients who are at elevated
risk for falls and fracture,12 with supplementation of 800 to 1000
IU/d for elderly adults with suboptimal levels.
Currently available pharmacologic options for osteoporosis
approved by the Taiwan Food and Drug Administration include
bisphosphonate alendronate (ALN). Treatment with ALN has been
shown to increase bone mass and reduce the incidence of
fractures, including hip and vertebral fractures, in postmenopausal
women with osteoporosis.14,15 Combination tablets, including a
once-weekly formulation of ALN 70 mg plus vitamin D3 (either
2800 or 5600 IU) in a single tablet, have been developed to ensure
that patients with osteoporosis receiving treatment with ALN also
receive adequate vitamin D3 to help reduce the risk of vitamin D
insufﬁciency and deﬁciency. Previous open-label, 2-period, cross-
over studies showed that ALN/vitamin D3 combination tablets
(either 2800 or 5600 IU vitamin D3) were bioequivalent to an
70-mg ALN tablet with respect to ALN bioavailability, and that the
bioavailability of vitamin D3 was similar in the combination tablets
and when vitamin D3 was administered alone.16
The objective of our study (protocol No. 330-00) was to
demonstrate bioequivalence between 70 mg ALN/ 5600 IU vitamin
D3 (ALN/D5600) combination tablets and coadministration of
corresponding doses of 70 mg ALN and 5600 IU vitamin D3 (2 
2800 IU) as individual tablets, in healthy male and female Asian
volunteers, to support registration in Taiwan, and to assess safety
and tolerability. Of note, the present study used a newly devel-
oped, sensitive plasma assay to determine bioequivalence based
on the assessment of the pharmacokinetic (PK) characteristics of
ALN in plasma, rather than the total urinary excretion method that
has been used historically.Methods
Participants
Adults aged 18 to 85 years, in good health (based on medical
history, physical examination, vital sign measurements, and labo-
ratory safety tests), and with a body mass index r30 were
eligible. Women with reproductive potential required a negative
pregnancy test and use of appropriate contraception other than
oral or hormone-based methods 14 days before study entry
through 14 days poststudy. Volunteers were excluded if they had
an estimated creatinine clearance r80 mL/min based on the
Cockcroft-Gault equation; were unable to refrain from using any
medication, beginning approximately 2 weeks (or 5 half-lives,
whichever was longer) before administration of the ﬁrst dose of
study drug; used active vitamin D3 compounds within 10 days before
study entry; received a high dose of vitamin D3 (45000 IU) within
4 weeks before study entry; or had a 25(OH)D level o15 ng/mL at
screening. Subjects were also excluded if they received regular,
prolonged sun exposure and were unable to avoid this exposure
during the study. Subjects were required to limit direct sunlight
exposure at least 10 days before the ﬁrst dose and throughout the
study, to apply sunscreen (at least 45 SPF) if anticipating exposure to
direct sunlight for 41 hour, and to avoid most dairy products,
vitamin D3-fortiﬁed foods, and foods known to be high in vitamin D3.
Study design
This was a single-dose, open-label, randomized, 2-period,
crossover study to establish bioequivalence between ALN/D5600combination tablets and coadministration of corresponding doses
of 70 mg ALN and 5600 IU vitamin D3 (2  2800 IU) as individual
tablets in healthy male and female Asian volunteers, to support
registration in Taiwan. Subjects were assigned an allocation
number for open-label treatment using a computer-generated
allocation schedule. In the 2 treatment periods, subjects received
1 of 2 single-dose oral treatments in a randomized order: 1 tablet
of ALN/D5600, or 1 tablet of 70 mg ALN and 2 tablets of 2800 IU
vitamin D3. For both treatments, subjects fasted overnight for at
least 8 hours, with the exception of water, which was restricted for
1 hour before and 1 hour after study-drug administration. All
doses of the study drug were administered with 240 mL water.
There was a minimum 12-day washout interval between treat-
ments. Blood samples for determination of plasma ALN concen-
trations were obtained predose and up to 24 hours postdose in
both treatment periods for all enrolled subjects. For the ﬁrst
40 subjects, blood samples for determination of serum vitamin
D3 (cholecalciferol) were obtained predose and up to 96 hours
postdose. Subjects were housed in the study unit and not exposed
to direct sunlight from 24 hours predose to 24 hours postdose
(96 hours postdose for subjects providing serum vitamin D3
samples), including the duration of the PK sampling periods; food
provided contained minimal, if any, vitamin D3.
The protocol was approved by the ethical review committee at
the study center and conducted in accordance with the guidelines
for Good Clinical Practice. All participants provided written
informed consent.
Assessments
Blood samples for determination of plasma ALN concentrations
were collected predose and 10, 20, 30, 40, and 50 minutes, and 1,
1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, and 24 hours postdose. Plasma
samples were assayed by PharmaNet Canada, Inc. (Québec,
Canada), using a validated HPLC method with a lower limit of
quantiﬁcation of 100 pg/mL. The analyte and its internal standard
alendronic acid-d6 were extracted from a 0.2 mL aliquot of human
plasma prepared with K2 EDTA, using a protein precipitation
procedure, followed by a solid phase extraction and a derivatiza-
tion step. The extracted samples were injected into a liquid
chromatograph equipped with a Zorbax 300-SCX (Agilent, Santa
Clara, CA, USA), 50  3 mm, 5 mm column. The mobile phase A
and B were mixtures of Milli-Q® type water and acetonitrile with
ammonium acetate and glacial acetic acid at different proportions.
The detection method used was tandem mass spectrometry.
Within-run accuracy and precision evaluations of the assay
were performed by analyzing replicate concentrations of alen-
dronic acid in human EDTA K2 plasma. The run consisted of a
calibration curve plus a total of 30 spiked samples; 6 replicates of
each of the lower and higher limits of quantitation; and low,
medium, and high quality control samples. The within-run coef-
ﬁcients of variation ranged between 1.27% and 4.47%. The within-
run percentages of bias ranged between –4.19% and 6.34%. The
data meet the pre-established acceptance criteria. The assay was
demonstrated to be selective for alendronic acid; common over-
the-counter medications as well as vitamin D3 were conﬁrmed not
to interfere with the analysis.
Blood samples for determination of serum vitamin D3 concen-
trations were collected at –18, –12, and –6 hours predose, and 1, 2,
4, 6, 8, 9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, 18, 20, 24, 48, 72,
and 96 hours postdose. Serum samples for vitamin D3 concen-
trations were assayed using a validated HPLC/tandem mass
spectrometry method with an lower limit of quantiﬁcation of
0.50 ng/mL.16
Plasma ALN and serum vitamin D3 concentrations and actual
sampling times relative to the time of dose were used to determine
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(version 5.2.1) (Certara, Princeton, NJ, USA). Individual baseline
vitamin D3 concentration adjustments were made using arith-
metic mean vitamin D3 concentrations at –18, –12, and –6 hours
before dosing. Baseline adjusted vitamin D3 concentrations were
obtained by subtracting the arithmetic mean predose vitamin D3
concentration from each individual postdose sample.
Safety and tolerability were assessed by the daily recording of
adverse experiences (AEs) throughout the study. A complete
physical examination was performed at pre- and poststudy visits,
and complete vital signs were obtained at prestudy, before each
study-drug administration, and poststudy. Laboratory safety tests,
including serum chemistry, hematology, and urinalysis, were
performed on samples obtained at the prestudy visit (approxi-
mately 2–4 weeks before the ﬁrst study drug administration) after
at least an 8-hour fast.
Statistical Analysis
Sample size and power
If the true geometric mean ratio (GMR) (ALN/D5600:ALN þ
vitamin D3) for the AUC0–last and Cmax of ALN was 0.99 and 0.95,
respectively, then a sample size of 60 subjects would provide this
study with 490% probability of observing the 90% CIs of 2 ALN
end points to be contained within a range of 0.80 to 1.25,17
assuming a nonnegative correlation between the 2 test statistics
for AUC0–1 and Cmax of ALN. If the true GMR for the AUC0–80h and
Cmax of vitamin D3 was 0.94, then a sample size of 36 subjects
would provide this study with 490% probability of observing the
90% CIs of the 2 end points to be contained within the range of
0.80 to 1.25, assuming a nonnegative correlation between the
2 test statistics for AUC0–80h and Cmax. For these calculations, the
within-subject SD of 0.20 (log scale) for the AUC0–80h and Cmax of
vitamin D3 was obtained from internal data (MK-0217A P253). The
within-subject SD of 0.30 (log scale) for the AUC0–last and Cmax of
ALN was obtained from Rhim et al.18 A nonnegative correlation
among the 4 primary end points was assumed for the calculations.Statistical methods
Statistical and PK analysis was conducted by Cytel Inc. (Cam-
bridge, MA, USA). There were 4 primary end points in this study:
ALN AUC0–last, ALN Cmax, vitamin D3 AUC0–80h, and vitamin D3 Cmax.
The PK parameters for ALN (AUC0–last, AUC0–1, and Cmax) and
vitamin D3 (unadjusted AUC0–80h and Cmax) following a single oral
dose of ALN/vitamin D3 combination tablet or coadministration of
ALN þ vitamin D3 were compared using a linear mixed-effects
model appropriate for a 2-period, crossover design. The model
contained period and treatment as ﬁxed effects, and subject as a
random effect. A log transformation was applied to the AUC and
Cmax before analysis.
The GMR of ALN AUC0–80h, AUC0–last, AUC0–1, and Cmax, and
vitamin D3 AUC0–80h and Cmax, unadjusted for endogenous vitamin
D3, were compared and bioequivalence deﬁned by the 90% CI
(based on the t-distribution) of the GMR for each primary end
point being contained within prespeciﬁed bounds (ie, 0.80–1.25).
Data were also examined for departures from the assumptions
of the statistical model and the use of a distribution-free method
considered if a serious departure from the assumptions of the
model was observed. Normality assumptions for the linear mixed
model were not met due to several extreme values. Therefore, a
nonparametric analysis that requires no normality assumption
about the distribution of the data was also conducted for the
ALN AUC0–last, AUC0–1, and Cmax data. Speciﬁcally, the Hodges-
Lehmann point estimate and the associated 90% CI were calculated
for the median of all pairwise differences of log-transformedAUC0–last, AUC0–1, and Cmax. The point estimate and 90% CI were
then exponentiated to the linear scale to obtain the estimate of
median ratio and the associated 90% CI.
Descriptive statistics were provided for other plasma PK
parameters (Tmax and t½). Minimum, median, and maximum were
provided for all PK parameters. In addition, the %CV for AUC and
Cmax were calculated according to the following formula: 100 
sqrt(exp(s2) – 1), where s2 is the observed variance on the natural
log scale. Harmonic mean and jackknife SD were provided for
apparent t1/2.Results
Subjects
From March 2012 through May 2012, 69 healthy male (n ¼ 53)
and female (n ¼ 16) volunteers (mean [range] age 29.0 [20–54]
years; height, 169.8 [150.0–192.0] cm; weight 56.0 [45.0–95.0] kg;
and body mass index, 22.9 [17.4–29.3]) were enrolled and were
included in the safety evaluation; 68 subjects completed the study
per protocol and were included in the PK analysis. One male
subject was discontinued from the study after dosing with con-
comitant ALN þ vitamin D3 in the ﬁrst treatment period due to
noncompliance with the protocol.
PK of ALN
Mean plasma concentration-time proﬁles of ALN following
administration of an ALN/D5600 combination tablet and coadmi-
nistration of corresponding doses of ALN and vitamin D3 as
individual tablets are shown in Figure 1A. One subject (a woman
aged 29 years) had no measurable plasma concentrations for ALN
on administration of the reference formulation (ALN þ vitamin
D3), so was excluded from the PK analysis for ALN.
Summary statistics for PK parameters of plasma ALN for
subjects with measurable PK in both treatment periods are shown
in Table I. The 90% CIs of the GMR for ALN AUC0–last and Cmax were
not contained within the prespeciﬁed bioequivalence bounds (ie,
0.80–1.25); the upper 90% CIs slightly exceeded 1.25 with actual
values of 1.253 and 1.289, respectively. However, the 90% CI of the
GMR for ALN AUC0–1 was contained within the bounds. The
median Tmax (1.2 hours and 1.0 hour for ALN/D5600 and ALN þ
vitamin D, respectively) and harmonic mean apparent t1/2
(7.8 hours and 7.7 hours, respectively) for plasma ALN were
comparable between treatments.
ALN exhibited higher within-subject variability for both AUC and
Cmax (%CV, 50%–51%) than was anticipated from the literature (%CV,
30% for both AUC and Cmax)18 when the study was designed.
With the nonparametric analysis that requires no normality
assumption about the distribution of the data and is less sensitive
to extreme values, the 90% CI for the ratio of the medians for AUC0–
last and AUC0–1 was within the bounds of bioequivalence (ie, 0.80–
1.25) (Table II). The upper bound of the 90% CI for ALN Cmax
median ratio marginally exceeded 1.25.
The individual ratios, GMRs, and corresponding 90% CIs of the
plasma AUC0–last, AUC0–1, and Cmax for ALN are shown in
Figure 2A.
PK of Vitamin D3
Baseline unadjusted vitamin D3
Mean plasma concentration-time proﬁles of serum unadjusted
vitamin D3 following administration of an ALN/D5600 combina-
tion tablet and coadministration of corresponding doses of ALN
and vitamin D3 as individual tablets are shown in Figure 1B.
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Figure 1. (A) Arithmetic mean (upper SD) plasma alendronate (ALN) and (B) serum
vitamin D3 concentration-time proﬁles following single-dose administration of
either an 70 mg ALN/5600 IU vitamin D3 combination tablet or coadministration of
corresponding doses of ALN and vitamin D3 as individual tablets.
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vitamin D3 for subjects with measurable PK data in both treatment
periods are shown in Table I. The 90% CIs of the GMR for vitamin
D3 AUC0–80h and Cmax, unadjusted for endogenous vitamin D3,
were contained within the prespeciﬁed bioequivalence bounds
(ie, 0.80–1.25). The median Tmax (12.5 hours and 13.5 hours,
respectively) and harmonic mean apparent t1/2 (29.9 hours andTable I
Summary results for pharmacokinetic parameters of plasma alendronate (ALN) and seru
combination tablet or corresponding doses of ALN and vitamin D3 as individual tablets
Pharmacokinetic parameter ALN/D5600 combination tablet ALN þ vita
n GM* 95% CI n
Plasma ALN
AUC0–last*, ng h/mL 67 111.71 96.72–129.03 67
AUC0–1*, ng h/mL 67 116.73 101.18–134.66 67
Cmax*, ng/mL 67 36.48 31.46–42.30 67
Tmax‡, h 67 1.2 0.5–2.0 67
Apparent t1/2§, h 67 7.8 1.6 67
Serum vitamin D3
AUC0-80h*, ng h/mL 40 382.81 318.83–459.62 40 4
Cmax*, ng/mL 40 10.45 8.86–12.32 40
Tmax‡, h 40 12.5 9.0–24.1 40
Apparent t1/2§, h 40 29.9 8.8 40
GM ¼ geometric mean.
n GM computed from least squares estimate from a linear mixed-effects model perf
† %CV, derived from variance components, provides an estimate of the pooled with
‡ Median, minimum, and maximum reported for Tmax.
§ Harmonic mean and jackknife SD provided for apparent t1/2.31.2 hours, respectively) for baseline unadjusted serum vitamin D3
were comparable between ALN/D5600 and ALN þ vitamin D3
treatments.
The individual ratios, GMRs, and corresponding 90% CIs of the
serum unadjusted AUC0–80h and Cmax for vitamin D3 are shown in
Figure 2B.
Baseline adjusted vitamin D3
For most subjects, postdose vitamin D3 levels were above
predose levels. However, in some subjects, vitamin D3 levels
declined to such an extent that at 80 hours postdose, they had
substantially lower vitamin D3 concentrations than their predose
values. In some instances, this decline resulted in negative con-
centration values when adjusted for predose vitamin D3. The
GMRs (90% CI) of serum vitamin D3 after baseline correction were:
1.101 (90% CI, 0.895–1.356) and 1.049 (90% CI, 0.893–1.231) for
AUC0–80h and Cmax, respectively. Whereas both point estimates and
the entire 90% CI for Cmax were within the prespeciﬁed bioequi-
valence bounds of 0.80 to 1.25, the upper limit of the 90% CI for
AUC0–80h fell outside these bounds.
Safety and Tolerability
Of the 69 subjects included in the safety analysis (1 of whom
did not receive the combination tablet), 51 reported a total of 128
clinical AEs, of which 125 were considered by the investigator to
be possibly related to the study drug. All AEs were transient and
considered mild in intensity by the investigator. There were no
serious AEs reported and no subjects discontinued because of an
AE. Two laboratory AEs were reported at prestudy: alanine amino-
transferase increased for 1 subject and aspartate aminotransferase
increased for a second subject. There were no consistent
treatment-related changes in routine clinical safety parameters,
including vital signs and physical examination.
The most common drug-related AEs were arthralgia (reported
by 25 and 27 subjects after receiving ALN/D5600 and ALN þ
vitamin D3, respectively), pyrexia (12 vs 10 subjects), and headache
(9 vs 10 subjects). Gastrointestinal disorders were reported in
4 and 6 patients, respectively, and included abdominal distension,
diarrhea, vomiting (all 1 subject each) and toothache (2 subjects)
in the ALN/D5600 group, and diarrhea (5 subjects), toothache
(2 subjects), and nausea (1 subject) in the ALN þ vitamin D3
group. There were no clinically meaningful differences inm vitamin D3 following administration of a 70 mg ALN/5600 IU vitamin D3 (D5600)
(linear mixed-model approach).
min D3 coadministration ALN/D5600:ALN þ vitamin D3
GM* 95% CI GMR 90% CI %CV†
103.08 88.20–120.48 1.084 0.937–1.253 50.45
108.02 92.63–125.98 1.081 0.935–1.249 50.21
32.82 28.25–38.13 1.112 0.959–1.289 51.29
1.0 0.3–3.0 – –
7.7 1.8 – –
01.86 351.01–460.08 0.953 0.827–1.098 37.68
10.64 9.29–12.19 0.982 0.854–1.130 37.14
13.5 10.0–16.0 – –
31.2 7.6 – –
ormed on the natural log-transformed values.
in-subject coefﬁcient of variation.
Table II
Summary results for pharmacokinetic parameters of plasma alendronate (ALN) and serum vitamin D3 after administration of 70 mg ALN and 5600 IU vitamin D3 as a
combination tablet or corresponding doses of ALN and vitamin D3 as individual tablets (nonparametric approach).
Treatment* n Minimum Median Maximum Interquartile range ALN/D5600: ALN þ vitamin D3 P value
AUC0–last*, ng h/mL
ALN/D5600 combination tablet 67 20.79 119.43 326.98 96.81 1.081 (0.944–1.243) 0.330
ALN þ vitamin D3 coadministration 67 19.16 100.17 496.04 107.25 –
AUC0–1*, ng h/mL
ALN/D5600 combination tablet 67 21.78 124.42 344.96 100.41 1.081 (0.941–1.244) 0.339
ALN þ vitamin D3 coadministration 67 19.91 104.49 510.21 108.82 –
Cmax*, ng/mL
ALN/D5600 combination tablet 67 7.11 40.08 102.73 33.41 1.120 (0.964–1.287) 0.190
ALN þ vitamin D3 coadministration 67 8.32 33.17 172.74 31.56 –
n Comparison: Hodges-Lehmann estimate of median ratio with 90% CI; P value from Wilcoxon signed-rank test. P value 40.1 indicates no statistically signiﬁcant
difference between the 2 treatments.
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coadministered dose of ALN and vitamin D3.Discussion
Although the 90% CIs of the observed GMRs for the plasma
AUC0–last and Cmax of ALN for subjects with measurable PK in both
treatment periods were not all contained within the prespeciﬁed
bounds for bioequivalence (ie, 0.80–1.25), the 90% CI of the
observed GMR for AUC0–1 of ALN was within the bounds. In
addition, the 90% CI of the ratio of medians for AUC0–last obtainedA
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Figure 2. Individual ratios, geometric mean ratios, and 90% CIs for (A) plasma
alendronate (ALN) AUC0–last, AUC0–1, and Cmax, and (B) serum unadjusted vitamin
D3 AUC0–80h, and Cmax. Dotted lines show the prespeciﬁed bioequivalence bounds
(0.80–1.25).from the nonparametric analysis was within the prespeciﬁed
bounds. The ALN/D5600 combination tablet and coadministration
of ALN þ vitamin D3 resulted in similar plasma concentration-
time proﬁles (Figure 1). This is supported by the fact that for both
GMRs the AUC0–last and Cmax were within the lower bound of the
90% CI of ALN AUC0–last and Cmax (there was only a minor excursion
of the upper bound of the 90% CI of ALN AUC0–last and Cmax), and
the entire 90% CI for AUC0–1 was within the bioequivalence
bounds (ie, 0.80–1.25).
The observed differences between ALN AUC0–last and Cmax are
not believed to be clinically signiﬁcant, in that the slightly higher
AUC0–last and Cmax of the ALN/D5600 combination tablet would
not be expected to result in an additional safety risk or to have an
inﬂuence on efﬁcacy compared with concomitant ALN þ vitamin
D3. This is because the differences were small and thus would
likely fall within the range experienced among the broad popula-
tion of patients using ALN, and because of the mechanism of action
of ALN, which relies on its deposition in bone. Incorporation of
ALN in bone over time is correlated clinically with increased bone
mass and reduced fracture risk,19 such that small differences in
AUC or Cmax are unlikely to have a major effect. In addition, based
on the highly variable drug characteristics of ALN and using the
proposed bioequivalence approach of the European Medicines
Agency for high variability values (intrasubject variability
430%),20 the Cmax of ALN falls within the expanded CI of 0.698
to 1.432. The highly variable drug status of ALN was not prespe-
ciﬁed in the hypothesis because this was the ﬁrst study conducted
by the sponsor to employ a newly developed assay for plasma ALN.
For this reason, internal data on which to base variability estimates
were lacking, and data from the literature on ALN were limited in
this regard.
The GMR and 90% CIs for unadjusted serum vitamin D3 for
AUC0–80h and Cmax were within the prespeciﬁed bioequivalence
bounds. After baseline correction of serum vitamin D3, both point
estimates and the entire 90% CI for Cmax were within the
prespeciﬁed bounds; however, the upper limit of the 90% CI for
AUC0–80h fell outside these bounds. This was because some
subjects had lower serum vitamin D3 concentrations at 80 hours
postdose than at predose. The likely explanation for this is the
restrictions that were placed on subjects to prevent exposure to
vitamin D3 except for study treatment, including the avoidance of
sun exposure and a diet containing minimal, if any, vitamin D3. The
baseline adjusted approach attempts to separate the contribution
of the administered vitamin D3 from endogenous vitamin D3 levels
on an individual basis, and in doing so, also adjusts for potential
differences in baseline vitamin D3 levels across periods. However,
this approach assumes that the endogenous level will remain
constant, which appeared to be incorrect for some subjects. The PK
parameters AUC0–80h and Cmax obtained from the data unadjusted
for baseline vitamin D3 concentrations are therefore favored
D.H. Wright et al. / Current Therapeutic Research 77 (2015) 116–121 121because this approach requires no assumptions; these data also
agree with those presented previously.16
Historically, the primary PK parameter of ALN was urinary
excretion of ALN. This was because plasma concentrations were
too low for analysis and elimination of bioavailable ALN is
essentially entirely via urinary excretion.19 However, urinary
analysis of ALN requires complex processes, is labor intensive,
and typically requires more than 200 subjects to demonstrate
bioequivalence.16 Recently, HPLC-MS/MS detection has been used
to measure plasma ALN levels. Use of a plasma-based assessment
required fewer subjects to demonstrate bioequivalence compared
with urine-based assessments.18 Once the extreme values in the
ALN data were accommodated, the data generated from this study
are in good agreement with those published previously using a
urine-based approach to demonstrate bioequivalence,16 which
supports the applicability of the plasma ALN assay. Because the
plasma t1/2 of ALN is long (up to 10 years), calculation of the
apparent terminal t1/2 and therefore the AUC0–1 may be under-
estimated. Hence, the AUC0–last was proposed as the primary PK
end point upon which to assess bioequivalence for ALN.
There were no clinically meaningful differences in tolerability
between the ALN/D5600 tablet and the coadministration of ALN þ
vitamin D3. Although the combination tablet showed slightly
higher Cmax and AUC0–last for ALN, the safety proﬁle remained
consistent with that of the marketed drug.
Conclusions
In this study of healthy male and female volunteers in Taiwan,
the ALN/D5600 combination tablet was considered bioequivalent
to coadministration based on ALN AUC0–1 and nonparametric
AUC0–last and unadjusted vitamin D3 AUC0–80h and Cmax. The
magnitude of the difference between ALN/D5600 and ALN þ
vitamin D3 for ALN AUC0–last and Cmax was not considered to be
clinically signiﬁcant, and both parameters fall within the expanded
CIs of the European Medicines Agency’s proposed bioequivalence
approach for high variability values. The combination tablet was
well tolerated, with no serious AEs reported, and is comparable to
the coadministration of corresponding doses of ALN and vitamin
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